MucoCept-HIV

About Osel

Osel is a pioneering, private biotech company developing a portfolio of Live Biotherapeutic Products (LBPs) to restore health by correcting microbiome imbalances (dysbiosis). With deep roots in the field, having filed its first IND in 2003, Osel's pipeline includes advanced programs in women's reproductive health and a groundbreaking oncology candidate, MO-03, which is set to begin a pivotal Phase 3 trial in combination with immunotherapy for kidney cancer. The company's strategy leverages its expertise in lactobacillus-based technology to address significant unmet medical needs in large markets, positioning it at the forefront of the emerging LBP sector.

Therapeutic Areas